Minnetronix Medical’s Neuro division said today it joined with Duke University to co-found The Neurapheresis Consortium, which aims to accelerate the advancement of Neurapheresis Therapy intended to treat patients with diseases affecting the central nervous system.
The company’s Neurapheresis therapy system is a minimally invasive platform which includes a dual lumen catheter designed to be placed in the lumbar spine to filter contaminated cerebral spinal fluid to remove blood and blood breakdown byproducts, the St. Paul, Minn.-based company said. The system then returns clean cerebral spinal fluid to the patient.
Read the whole story on our sister site, Medical Design & Outsourcing